Thyrocare Technologies reported a consolidated net profit of ₹51.33 crore for the quarter ended June 30, 2026, marking a 34% year-on-year increase from ₹38.29 crore in Q1FY25. The diagnostic services provider saw its revenue from operations rise 24% to ₹240.02 crore, up from ₹193.03 crore in the corresponding period last year, reflecting robust demand across its testing portfolio. This growth trajectory signals strong operating leverage as the company expands its network capacity, with earnings per share rising to ₹3.23 from ₹2.41 in the prior year quarter.

The results were approved by the Board of Directors on July 23, 2026, and disclosed under Regulation 30 and 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The statutory auditors, Price Waterhouse Chartered Accountants LLP, issued an unmodified limited review report on the unaudited financial results. Additionally, based on the recommendation of the Audit Committee, the Board re-appointed M/s. Ernst & Young LLP, Chartered Accountants, as Internal Auditors for the Financial Year 2026-27.

On a standalone basis, Thyrocare Technologies recorded a net profit of ₹50.17 crore, a 39% jump from ₹36.05 crore in Q1FY25. Revenue from operations stood at ₹225.66 crore, compared to ₹178.89 crore in the previous year’s quarter. The growth continued from Q4FY25, where consolidated revenue was ₹223.95 crore and net profit was ₹48.70 crore. The company’s equity share capital remained stable at ₹159.17 crore, following significant expansion earlier in FY25.

Segment-wise performance highlights the dominance of the core business. Diagnostic Testing Services contributed ₹226.21 crore in revenue, up from ₹178.33 crore in Q1FY25, with segment results before tax rising to ₹61.90 crore from ₹44.85 crore. Imaging Services generated ₹13.48 crore in revenue, down slightly from ₹14.04 crore, with segment results at ₹1.26 crore compared to ₹0.27 crore in the prior year quarter. The 'Others' segment contributed marginally with ₹0.33 crore in revenue.

What the Numbers Show

The divergence between revenue growth (24%) and net profit growth (34%) indicates improving operating leverage in the quarter. While both consolidated and standalone metrics showed strong double-digit growth, the slightly higher standalone profit margin suggests efficient cost management at the corporate level. The consistent rise in earnings per share, despite the significant dilution from increased share capital earlier in the fiscal year, underscores the underlying strength of the business model. Furthermore, the forfeiture of 3,733 equity stock options during the quarter adds to the available pool for future employee distributions, supporting long-term retention strategies.

Thyrocare Technologies Ltd's Board of Directors has in-principle approved the evaluation of a proposed demerger of its wholly-owned subsidiary Nueclear Healthcare Limited's radiology business undertaking. The strategic move, discussed at a board meeting on July 23, 2026, aims to transfer the radiology operations outside the group through a scheme of arrangement, slump sale, business transfer, or another appropriate structure. This restructuring is intended to streamline operations and optimize the group's portfolio.

The Proposed Restructuring is currently at an in-principle evaluation stage. Detailed terms will be placed before the Board of Directors of Nueclear Healthcare Limited at an appropriate time. Following this, necessary disclosures and filings will be made with the stock exchanges and other regulatory or statutory authorities as applicable.

Nueclear Healthcare Limited is engaged in advanced cancer diagnostics and nuclear medicine. The subsidiary operates PET-CT and CT imaging centres, provides nuclear medicine diagnostic services, and manufactures radiopharmaceuticals through its medical cyclotron facilities. These services support the early detection, diagnosis, staging, and monitoring of cancer and other complex diseases.

Thyrocare Technologies Ltd will ensure compliance with all applicable regulatory requirements, including under the Companies Act, 2013 and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, at each stage of the Proposed Restructuring. This includes timely intimation to the stock exchanges.

The board meeting commenced at 2:45 P.M. and concluded at 03:35 P.M. on July 23, 2026.